Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells

Biomedical Research

Volumn 31, Issue 6, 2010, Pages 401-411

  Yoshikawa, Kazuhito ^a   Hamada, Jun ichi ^a   Tada, Mitsuhiro ^a   Kameyama, Takeshi ^a   Nakagawa, Koji ^a   Suzuki, Yukiko ^a   Ikawa, Mayumi ^a   Hassan, Nur Mohammad Monsur ^a   Kitagawa, Yoshimasa ^a   Moriuchi, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; HEPARANASE; MATRIGEL; MATRIX METALLOPROTEINASE; MUTANT PROTEIN; PROTEIN P53; UROKINASE;

ARTICLE; CANCER INVASION; CELL MOTILITY; CODON; CONTROLLED STUDY; DOMINANT GENE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; POINT MUTATION; PROTEIN EXPRESSION;

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CODON; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; POINT MUTATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

FORMICIDAE;

EID: 78650831903     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.31.401     Document Type: Article

References (26)

1. Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, Takahashi O, Miyamoto M, Hamada J, Moriuchi T and Kondo S (2008) Prognostic values of matrix metalloprotein-ase family expression in human colorectal carcinoma. J Surg Res 146, 32-42.
2. Brachmann RK, Vidal M and Boeke JD (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93, 4091-4095.
3. Brosh R and Rotter V (2009) When mutants gain new powers: news from the mutant p53 feld. Nat Rev Cancer 9, 701-713.
4. Di Como CJ, Gaiddon C and Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19, 1438-1449.
5. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, VanMeir EG, Estreicheru A and Iggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967.
6. Frazier MW, He X, Wang J, Gu Z, Cleveland JL and Zambetti GP (1998) Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18, 3735-3743.
7. Hainaut P and Hollstein M (2000) p53 and human cancer: the frst ten thousand mutations. Adv Cancer Res 77, 81-137.
8. Hassan NM, Tada M, Hamada J, Kashiwazaki H, Kameyama T, Akhter R, Yamazaki Y, Yano M, Inoue N and Moriuchi T (2008) Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. Cancer Lett 270, 108-119.
9. Kueng W, Silber E and Eppenberger U (1989) Quantifcation of cells cultured on 96-well plates. Anal Biochem 182, 16-19.
10. Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M and Moriuchi T (1999) Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59, 4765-4769.
11. Merabet A, Houlleberghs H, Maclagan K, Akanho E, Bui TT, Pagano B, Drake AF, Fraternali F and Nikolova PV (2010) Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Biochem J 427, 225-236
12. Milner J and Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774.
13. Milner J, Medcalf EA and Cook AC (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11, 12-19.
14. Miyazaki YJ, Hamada J, Tada M, Furuuchi K, Takahashi Y, Kondo S, Katoh H and Moriuchi T (2002) HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells. Oncogene 21, 798-808.
15. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A and Fronza G (2003) Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22, 5252-5260.
16. Noskov SY, Wright JD and Lim C (2002) Long-range effects of mutating R248 to Q/W in the p53 core domain. J Phys Chem 106, 13047-13057.
17. Ohta H, Hamada J, Tada M, Aoyama T, Furuuchi K, Takahashi Y, Totsuka Y and Moriuchi T (2006) HOXD3-overexpression increases integrin alpha v beta 3 expression and deprives E-cadherin while it enhances cell motility in A549 cells. Clin Exp Metastasis 23, 381-390.
18. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10, 431-442.
19. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165.
20. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phe-notype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28, 622-629.
21. Sakuragi N, Watari H, Ebina Y, Yamamoto R, Steiner E, Koelbl H, Yano M, Tada M and Moriuchi T (2005) Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 116, 514-519.
22. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP and Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276, 39359-39367.
23. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M and Blandino G (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277, 18817-18826.
24. Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y and Abe H (1996) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 67, 447-450.
25. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfnger N, Oren M and Rotter V (2004) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64, 8318-8327.
26. Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V and Oren M (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22, 5667-5676.